• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Genmab A/S

< Previous 1 2 3 Next >
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025
July 16, 2025
From Genmab A/S
Via GlobeNewswire
Genmab Announces Changes to its Executive Committee
July 01, 2025
From Genmab A/S
Via GlobeNewswire
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial
June 02, 2025
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
May 22, 2025
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress
May 14, 2025
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab Announces Financial Results for the First Quarter of 2024
May 08, 2025
From Genmab A/S
Via GlobeNewswire
Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
May 01, 2025
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
May 01, 2025
From Genmab A/S
Via GlobeNewswire
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025
April 15, 2025
From Genmab A/S
Via GlobeNewswire
TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer
March 31, 2025
From Genmab A/S
Via Business Wire
Tickers GMAB
TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy
March 27, 2025
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.
March 21, 2025
From Genmab A/S
Via GlobeNewswire
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
March 10, 2025
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
March 10, 2025
From Genmab A/S
Via GlobeNewswire
EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma
February 20, 2025
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab Publishes 2024 Annual Report
February 12, 2025
From Genmab A/S
Via GlobeNewswire
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024
January 22, 2025
From Genmab A/S
Via GlobeNewswire
Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
December 09, 2024
From Genmab A/S
Via Business Wire
Tickers GMAB
Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis
December 08, 2024
From Genmab A/S
Via Business Wire
Tickers GMAB
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
December 07, 2024
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab Announces Financial Results for the First Nine Months of 2024
November 06, 2024
From Genmab A/S
Via GlobeNewswire
Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting
November 05, 2024
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024
October 15, 2024
From Genmab A/S
Via GlobeNewswire
Major Shareholder Announcement
October 04, 2024
From Genmab A/S
Via GlobeNewswire
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
September 15, 2024
From Genmab A/S
Via Business Wire
Tickers GMAB
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
August 19, 2024
From Genmab A/S
Via Business Wire
Tickers GMAB
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
August 19, 2024
From Genmab A/S
Via GlobeNewswire
Genmab Announces Changes to its Executive Committee
August 16, 2024
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab Announces Financial Results for the First Half of 2024
August 08, 2024
From Genmab A/S
Via GlobeNewswire
Genmab Updates 2024 Financial Guidance
August 08, 2024
From Genmab A/S
Via GlobeNewswire
< Previous 1 2 3 Next >
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap